Keywords
Biography
I am a Senior Research Associate in the Medicines Intelligence Research Program in the School of Population Health. I also work as an endocrinologist in St Vincent's Clinic and in Randwick. I have a Master of Medicine (Clinical Epidemiology) from the University of Sydney and in 2025 was awarded a PhD from UNSW Sydney. My PhD focussed on the effective and safe use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), critical medicines in the...view more
I am a Senior Research Associate in the Medicines Intelligence Research Program in the School of Population Health. I also work as an endocrinologist in St Vincent's Clinic and in Randwick. I have a Master of Medicine (Clinical Epidemiology) from the University of Sydney and in 2025 was awarded a PhD from UNSW Sydney. My PhD focussed on the effective and safe use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), critical medicines in the treatment of type 2 diabetes, heart failure and chronic kidney disease. My research work focuses on pharmacotherapy for cardiovascular-kidney-metabolic (CKM) syndrome including SGLT2i and glucagon-like peptide-1 receptor agonists (GLP-1 RA). It is of great importance that those with greatest need for these medicines can receive them.
My Grants
2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Collaborative Grant, $30,000
My Qualifications
Bachelor of Medicine Bachelor of Surgery Honours Class 1, UNSW Sydney (2011)
Fellow of the Royal Australasian College of Physicians (Adult Medicine Division - specialist endocrinologist) (2018)
Master of Medicine (Clinical Epidemiology), University of Sydney (2019)
Doctor of Philosophy (PhD), UNSW Sydney (2025)
My Awards
2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Symposium Best Oral Presentation
My Research Activities
As an endocrinologist, I have a strong clinical and academic interest and expertise in diabetes pharmacotherapy, specifically medicines with major cardiac and renal benefits - sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). I have explored the implementation of SGLT2i through a mixed-methodology approach, having both undertaken novel qualitative and pharmacoepidemiology studies. As a member of the Medicines Intelligence Research Program, I have explored the uptake of SGLT2i and GLP-1 RA in people with type 2 diabetes in New South Wales and Australia. These projects have shown a considerable underutilisation of these cardiorenal medicines, as well as geographic variation in their use. We are expanding our implementation studies about these medicines.
I also have an interest in the perioperative management of people using SGLT2i and GLP-1 RA, and have published reviews and works on this subject.
Contact
ORCID as entered in ROS
https://orcid.org/0009-0002-0538-2661